Alembic & Alembic Pharma


(bbbhutra) #412

Alembic Pharma on Friday has entered into the oncology segment by inaugurating anti-cancer manufacturing facility at Panelav, Halol, Gujarat.

The manufacturing facility is designed with containment control automated standards and major equipment imported from Europe. With this facility, Alembic Pharma will commence exporting oncology products to US, Middle East, North Africa, Australia and South Africa.


(Mukesh Tolani) #413

A rare precedent this in the Indian corporate scene.

Minority shareholders demand a seat in the board of directors of Alembic Ltd.


(ragav) #414

Q118 results have factored in the news of lower sales and DE - Growth in USA in its stock price .
A 12 % lower growth in revenues EBITDA Margins Post R&D at 16 % vs 21%

Of the 3 vertices of the company Indian formulations, International formulations and Api Business there seems to be only 2 % growth in API business. Other 2 verticals have dragged down growth .

The company has said it has filed for 4 DMF, and as per the USFDA ORANGE BOOK the 4 DMF for this Q118 are

  1. Macitentan - 93 mm $ in sales
  2. Riociguat - 50 mm $ in sales
  3. Afatinib dimaleate - 36 mm $ in sales
  4. Ivacaftor - 24 mm $ in sales

So I can see not all the drugs at having a big market sales when compared to other products like Aripiprazole gAbilify, and there could be meaningful competition too in these drugs. I would watch the launches and DMF being filed by the company in future Quarters and the company has said that it would be launched 100 Anda commencing 2018 so which would be a great revenue drive I believe.

Disc : Invested in ALEMBIC pharma , opinions are my own and can be biased.


(arunjacob) #415

alembic pharma sells its baddi formulation manufacturing facility .Not sure of the motives here . could this be a red signal ?


(Nityanand) #416

Dont know about the sale of Baddi unit here, but they are coming up with new facilities at Panelav. Construction of a new plant will start in few months.

I got to know this as my job profile allows me to visit the clients in Gujarat and I get to know about the developments.

Disc: No investment in Alembic


(Rohit Ojha) #417

As per press release the Baddi plant contribution was negligible.
If you go 2-3 years back annual reports, it said that this plant was formulations plant for India and emerging markets. It seems that the plant either had low capacity or was not operational. Anyhow, there must be a land value at least.


(bbbhutra) #418

Transcript of Q1 2018

Alembic Pharma.pdf (101.4 KB)


(Vikas Pandey) #419

alembic pharma bought Orit Laboratories LLCac2b6749-34d8-49eb-a355-c14be6433ad3.pdf (666.7 KB)


(bbbhutra) #420

(Rohit Ojha) #421

The recent ANDA approvals of Alembic have been petty change. Really very small market sizes. I wonder whether these will make any difference to their numbers. Another way to look at it is that there will not be much competition for such molecules. Could be worth asking in concall.

Also another news announced yesterday.
This is to inform the exchange that our Associate Company, Rhizen Pharmaceuticals SA has released a Press Release announcing that the USFDA has granted Fast Track Designation for RP6530 (tenalisib


(Gaurav Chandak) #422

Alembic Pharmaceuticals Limited today announced that the company has received
approval from the US Food & Drug Administration (USFDA) for its Abbreviated New
Drug Application (ANDA) Bupropion Hydrochloride Tablets USP, 75 mg and 100 mg.
The approved ANDA is therapeutically equivalent to the reference listed drug product
(RLD), Wellbutrin® Tablets, 75 mg and 100 mg, of GlaxoSmithKline LLC. Bupropion
Hydrochloride Tablets USP, 75 mg and 100 mg is indicated for the treatment of
major depressive disorder.
Bupropion Hydrochloride Tablets USP, 75 mg and 100 mg, have an estimated
market size of US$ 37 million for twelve months ending December 2017 according to
IMS.
Alembic now has a total of 72 ANDA approvals (64 final approvals and 8 tentative
approvals) from USFDA.